MedTrace Logo

Prevalence of Epilepsy and Sleep Wake Disorders in Alzheimer Disease

NCT03617497 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2023-10-13

No results posted yet for this study

Summary

Alzheimer disease is the most common of the neurodegenerative diseases. Epilepsy and sleep wake disorders are co-morbid conditions of Alzheimer disease. The investigators propose a prospective study using long-term EEG monitoring in combination with polysomnography to determine prevalence of epilepsy and sleep wake disorders in Alzheimer disease, and correlate these findings with clinical data, Alzheimer disease biomarkers and imaging studies (MRI and amyloid/tau-PET). In selected patients, the investigators will perform EEG studies with foramen ovale electrodes. The ultimate goal is to improve the outcome of patients with Alzheimer disease by early treatment of epilepsy and restoring sleep-wake disturbances.

Conditions

  • Alzheimer Disease
  • Alzheimer Dementia
  • Epilepsy
  • Sleep Wake Disorders

Interventions

DIAGNOSTIC_TEST

scalp EEG and polysomnography

48 hour 22 channel EEG with polysomnography

DIAGNOSTIC_TEST

scalp EEG with foramen ovale electrodes with polysomnography

long-term scalp EEG with additional foramen ovale electrodes with polysomnography

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Wim Van Paesschen, MD PhD · UZ and KU Leuven

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03617497 on ClinicalTrials.gov